(Q36641573)

15 August 2017

1 reference

title

Nasal delivery of antimigraine drugs: clinical rationale and evidence base (English)

1 reference

15 August 2017

Alan Rapoport

1

1 reference

15 August 2017

Paul Winner

series ordinal

2

1 reference

15 August 2017

language of work or name

1 reference

1 November 2006

1 reference

15 August 2017

1 reference

15 August 2017

volume

46 Suppl 4

1 reference

15 August 2017

page(s)

S192-201

1 reference

Intranasal medications for the treatment of migraine and cluster headache

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2006.00603.X

Transport of drugs from the nasal cavity to the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2006.00603.X

The biopharmaceutical aspects of nasal mucoadhesive drug delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2006.00603.X

Delivery of neurotrophic factors to the central nervous system: pharmacokinetic considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2006.00603.X

Avenues for entry of peripherally administered protein to the central nervous system in mouse, rat, and squirrel monkey

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2006.00603.X

Endocytic and exocytic pathways of the neuronal secretory process and trans-synaptic transfer of wheat germ agglutinin-horseradish peroxidase in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2006.00603.X

The nasal mucociliary clearance: relevance to nasal drug delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2006.00603.X

Butorphanol (Stadol): a study in problems of current drug information and control.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2006.00603.X

Bioavailability of dihydroergotamine in man

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2006.00603.X

Dihydroergotamine nasal spray for the acute treatment of migraine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2006.00603.X

Acute treatment of migraine with dihydroergotamine nasal spray. Dihydroergotamine Working Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2006.00603.X

Sumatriptan: a decade of use and experience in the treatment of migraine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2006.00603.X

Intranasal sumatriptan for the acute treatment of migraine. International Intranasal Sumatriptan Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2006.00603.X

A randomized, double-blind, placebo-controlled study of sumatriptan nasal spray in the treatment of acute migraine in adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2006.00603.X

Consistency of response to sumatriptan nasal spray across patient subgroups and migraine types

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2006.00603.X

Speed of onset and efficacy of zolmitriptan nasal spray in the acute treatment of migraine: a randomised, double-blind, placebo-controlled, dose-ranging study versus zolmitriptan tablet

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2006.00603.X

Tolerability and consistency of effect of zolmitriptan nasal spray in a long-term migraine treatment trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2006.00603.X

Sumatriptan relieves migrainelike headaches associated with carbon monoxide exposure

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2006.00603.X

10.1111/J.1526-4610.2006.00603.X

21 January 2018

Identifiers

DOI

1 reference

15 August 2017

1 reference